Recent research has shown that the binding of SRSF6 with lncRNA colorectal neoplasia differentially expressed (CRNDE) leads to abnormal physiological regulation of the AS of SRSF6, which results in resistance to oxaliplatin and 5-FU treatment both in vivo and in vitro.270 NOVA2 is generally upregulated in GC cells and produces new AS transcripts, including causing its downstream target Rap Guanine Nucleotide Exchange Factor 6 (RapGEF6) exon 21a inclusion, playing an important role in tumor angiogenesis.271. This evidence concerns the gene SRSF6 and gastric cancer.